REG - Oxford Cannabinoid - Appointment of General Counsel & Notice of Results

Oxford Cannabinoid Technologies HoldingsAnnouncement

16/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230116:nRSP6819Ma&default-theme=true

RNS Number : 6819M  Oxford Cannabinoid Tech.Holdings  16 January 2023

 

Oxford Cannabinoid Technologies Holdings plc

("OCTP" or the "Company")

 

Appointment of General Counsel & Company Secretary

Notice of Results

& Analyst and Investor Presentations

 

Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company
developing prescription cannabinoid medicines for approval by global
regulatory agencies and targeting the US$ multi-billion pain market, is
pleased to announce the appointment of Robin ("Rob") Bennett as General
Counsel and Company Secretary. Rob joined the Company in December 2022 as
General Counsel and was appointed Company Secretary on 12 January 2023.

Rob brings a wealth of experience and expertise to the Company from his role
as General Counsel and Company Secretary at Bestway Wholesale (formerly
Costcutter Supermarkets Group). He has over 15 years of UK and international
experience across multiple sectors, including retail, fast-moving consumer
goods, manufacturing, innovation and FinTech. His knowledge in legal, risk and
compliance has been gained through working with SMEs and quoted companies such
as SABMiller plc. He has been recognised for his work by being listed in Legal
500's GC Powerlists in 2021 and 2022 and as a Team of the Year finalist at The
Lawyer Awards in 2021.

Clarissa Sowemimo-Coker, interim CEO said: "We are delighted to welcome Rob to
OCTP. His experience in the UK and internationally is hugely beneficial to us,
as is his expertise in M&A. He is quickly becoming a valued member of our
team."

Notice of Results & Analyst and Investor Presentations

The Company intends to announce results for the six-month period ended 31
October 2022 on Monday 23 January 2023.

Analyst Briefing, 09.30, Monday 23 January 2023

A briefing for analysts will be held at 09.30 GMT on the day of the results.

 

Analysts interested in attending should contact Walbrook PR by emailing
oxcantech@walbrookpr.com (mailto:oxcantech@walbrookpr.com) or by calling 020
7933 8780.

 

Investor Presentation, 16.30, Monday 23 January 2023

A live online presentation via the Investor Meet Company platform will also be
held at 16.30 GMT on Monday 23 January 2023, which is open to all existing
and potential shareholders.

 

Investors can sign up to Investor Meet Company for free and add to meet Oxford
Cannabinoid Technologies Holdings plc via:
https://www.investormeetcompany.com/oxford-cannabinoid-technologies-holdings-plc/register-investor
(https://www.investormeetcompany.com/oxford-cannabinoid-technologies-holdings-plc/register-investor)

 

Investors who already follow OCTP on the Investor Meet Company platform will
automatically receive an invitation to the event.

 

The Directors of the Company accept responsibility for the content of this
announcement.

 

  Enquiries:

Oxford Cannabinoid Technologies Holdings plc  +44 (0)20 3034 2820

 Clarissa Sowemimo-Coker (Interim CEO)         clarissa@oxcantech.com

 Cairn Financial Advisers LLP

 Emily Staples                                 +44 (0)20 7213 0897

 Jo Turner                                     +44 (0) 20 7213 0885

 Axis Capital Markets Limited

 Kamran Hussain                                +44 (0)20 3026 0320

 Richard Hutchison

 finnCap Ltd

 Geoff Nash/Fergus Sullivan                    +44 (0) 20 7220 0500

 Nigel Birks (ECM)

 Walbrook PR Limited                           +44 (0)20 7933 8780

 Paul Vann/Nick Rome                           +44 (0)7768 807631

                                               oxcantech@walbrookpr.com

About Oxford Cannabinoid Technologies Holdings Plc:

Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the holding company
of a pharmaceutical Group developing prescription cannabinoid medicines
targeting the U$ multi-billion global pain market.

 

OCTP currently has a portfolio of four drug development programmes. Its lead
compound, OCT461201, will initially target neuropathic and visceral pain
(including irritable bowel syndrome ("IBS") and chemotherapy induced
peripheral neuropathy ("CIPN")), with Phase 1 clinical trials, aimed at
demonstrating safety and tolerability, due to commence in the near term. Trial
results are expected in Q2 2023.
(https://www.londonstockexchange.com/news-article/OCTP/updates-on-lead-programme-1-and-programme-2/15391762)
The global market for CIPN alone was valued at US$1.61bn in 2020 and is
forecast to reach US$2.37bn by the year 2027.

 

OCTP's drug development pipeline, comprises  both natural and synthetic
compounds, and includes compounds targeting trigeminal neuralgia, a severe
type of face pain, and cannabinoid derivatives targeting pain and potentially
other therapeutic areas. Having established an exclusive license agreement
with Canopy Growth Corporation for their entire pharmaceutical cannabinoid
derivative library, OCTP now has a portfolio of over 400 derivatives and
intellectual property rights including 14 patent families and associated
research data.

 

OCTP has a clearly defined path to commercialisation, revenues and growth. The
Group is developing drug candidates through clinical trials to gain regulatory
approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe
them with confidence. OCTP's portfolio aims to balance risk, value and time to
market, whilst ensuring market exclusivity around all its key activities.

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward
looking statements. Forward looking statements are identified by their use of
terms and phrases such as ''believe'', ''could'', "should" ''envisage'',
''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect",
''will'' or the negative of those, variations or comparable expressions,
including references to assumptions. These forward-looking statements are not
based on historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of operations,
performance, future capital and other expenditures (including the amount,
nature and sources of funding thereof), competitive advantages, business
prospects and opportunities. Such forward looking statements reflect the
Directors' current beliefs and assumptions and are based on information
currently available to the Directors.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORGPUPPGUPWGUW